A A A
DE
Bereichsnavigation

Interim Report for the First Quarter of 2016: financial year starts well – strategic focus on digitalisation and promoting innovation

Previous
RHÖN-KLINIKUM AG | 06.05.2016

Interim Report for the First Quarter of 2016: financial year starts well – strategic focus on digitalisation and promoting innovation

  • 205,578 patients treated
  • Revenues stand at € 291.5 million
  • EBITDA of approx. € 68 million includes positive one-off effect of roughly € 36 million
  • Outlook for 2016: Revenues between € 1.17 billion and € 1.20 billion,
  • EBITDA between € 155 million and € 165 million

In the first quarter of the current financial year over 200,000 (205,578 to be precise) patients were treated in the hospitals of RHÖN-KLINIKUM AG. Revenues for the same period amounted to € 291.5 million with earnings before interest, taxes, depreciation and amortisation (EBITDA) standing at € 67.9 million. This also includes a positive special influence in the amount of € 36.4 million after dissolving provisions for warranty claims from the sale of a total of 43 facilities to Helios/Fresenius which was completed in 2014. The current financial figures are therefore not directly comparable with those of previous years due to these ongoing effects on the balance sheet.

Annual General Meeting on 8th June 2016

The Board of Management and Supervisory Board shall propose to this year’s ordinary Annual General Meeting on 8th June 2016 in Frankfurt/Main the distribution of a dividend in the amount of € 0.80 per non-par share. This results in a dividend amount of almost € 54 million based on the current number of roughly 67 million shares. RHÖN-KLINIKUM AG also intends the shareholders to be able to participate extensively in the future success of the Company by means of dividend payout ratios which are above 60 %, thereby allowing the Company to remain in M-Dax with an attractive dividend value.

Outlook

For financial year 2016 we expect revenues of € 1.17 billion to € 1.20 billion and earnings before interest, taxes, depreciation and amortisation (EBITDA) of between € 155 million and € 165 million. Positive and negative one-off effects, the size of which will be a low to medium two digit million figure, will continue to influence the corporate results during this financial year as well and will partially cancel each other out. They mainly result from handling the transaction with Fresenius/Helios, the initial consolidation and integration of the municipal hospital in Bad Neustadt, special budgets for innovation and e-health, unresolved accounting issues and setting up a substantial out-patient clinic at the university hospital in Marburg. We assume that regulatory restrictions will also have a negative impact on our organic growth in 2016. Against this background we must expect a drop in revenues of roughly 1 % for the current financial year.“With an extensive number of initiatives and measures we are pressing ahead with the digitalisation process in our Company and are also investing in targeted innovation in order to provide our patients with the best possible medical care together with a direct link to university standards, also with an eye to the future,” Dr. Martin Siebert stated. The pioneering role in both areas is also a precondition for pressing ahead with the campus concept. “We are now placing greater emphasis on the link between in patient and out-patient medical care including other areas, such as rehabilitation, in order to ensure long-term, first-class medical care for our patients who are particularly in rural areas. We shall also continue to strengthen and develop this unique position which we have in the market,” Siebert continued.